Lincoln Pharmaceuticals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Lincoln Pharmaceuticals Limited Pharmaceutical Export Portfolio Dataset — 40 Products, $78.7M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Lincoln Pharmaceuticals Limited — Pharmaceutical Exporter Profile (2026) | 40 Products, $78.7M Trade | TransData Nexus

Lincoln Pharmaceuticals Limited

Indian Pharmaceutical Exporter · Antimalarial & Antiparasitic Specialist · $78.7M Total Trade · DGFT Verified

Lincoln Pharmaceuticals Limited is an Indian pharmaceutical exporter with a total trade value of $78.7M across 40 products in 15 therapeutic categories. Based on 1,763 verified export shipments from Indian Customs (DGFT) records, Lincoln Pharmaceuticals Limited is the #1 Indian exporter in 8 products including Diclofenac, Gentamicin, Azithromycin. Top exports include Artesunate ($9.0M), Diclofenac ($8.9M), Metronidazole ($7.0M).

Lincoln Pharmaceuticals Limited — Export Portfolio & Destination Treemap

Lincoln Pharmaceuticals Limited pharmaceutical export portfolio — 40 products across 15 therapeutic categories. Source: Indian Customs (DGFT).

Who is Lincoln Pharmaceuticals Limited? — Company Overview & Market Position

Lincoln Pharmaceuticals Limited, established in 1979, is a prominent Indian pharmaceutical company headquartered in Ahmedabad, Gujarat. The company specializes in the manufacturing and trading of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Its diverse product portfolio spans 15 therapeutic categories, such as anti-infectives, respiratory treatments, gynecology, cardiology, central nervous system disorders, anti-diabetic, and anti-malarial medications.

In January 1995, Lincoln Pharmaceuticals transitioned from a partnership firm to a public limited company, with the Corporate Identification Number (CIN) L24230GJ1995PLC024288. The company is listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) under the ticker symbol "LINCOLN." As of March 13, 2026, Lincoln Pharmaceuticals reported a market capitalization of approximately ₹12.09 billion, with a revenue of ₹6.52 billion for the fiscal year ending March 2025.

The company employs over 1,700 individuals, reflecting its significant presence in the Indian pharmaceutical industry. Its manufacturing facilities are located in Khatraj and Mehsana, Gujarat, adhering to international quality standards. The official website for Lincoln Pharmaceuticals is www.lincolnpharma.com.

What Does Lincoln Pharmaceuticals Limited Export? — Product Portfolio Analysis

Product Portfolio — Top 30 by Export Value

Lincoln Pharmaceuticals Limited exports 40 pharmaceutical products across 15 therapeutic categories. Market leader (#1 exporter) in 8 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Artesunate	Antimalarial & Antiparasitic	$9.0M	191	4.4%	5
2	Diclofenac	Analgesics & Antipyretics	$8.9M	179	2.5%	1
3	Metronidazole	Advanced Antibiotics	$7.0M	155	3.5%	5
4	Gentamicin	Antibiotics	$5.8M	116	11.4%	1
5	Azithromycin	Antibiotics	$4.8M	97	2.6%	1
6	Artemether	Antimalarial & Antiparasitic	$4.3M	86	0.5%	13
7	Clotrimazole	Antifungals	$4.3M	85	4.6%	3
8	Hydrocortisone	Corticosteroids	$2.9M	57	4.3%	2
9	Ceftriaxone	Advanced Antibiotics	$2.7M	54	0.9%	6
10	Nystatin	Antifungals	$2.6M	53	5.1%	3
11	Pantoprazole	Gastrointestinal	$2.6M	53	0.2%	7
12	Cetirizine	Antihistamines & Allergy	$2.1M	43	1.2%	11
13	Albendazole	Antimalarial & Antiparasitic	$1.7M	93	2.4%	8
14	Lansoprazole	Gastrointestinal	$1.7M	34	0.6%	4
15	Griseofulvin	Advanced Antifungals	$1.6M	34	3.5%	1
16	Amino	Nutritional Supplements	$1.2M	24	0.4%	10
17	Captopril	Cardiovascular	$1.1M	26	8.1%	1
18	Aminophylline	Respiratory & OTC	$1.1M	31	16.2%	1
19	Mebendazole	Antimalarial & Antiparasitic	$1.1M	22	8.0%	3
20	Atenolol	Cardiovascular	$1.1M	21	2.6%	6
21	Nifedipine	Cardiovascular	$995.2K	29	3.3%	7
22	Secnidazole	Advanced Antibiotics	$950.0K	19	3.1%	2
23	Metoclopramide	Gastrointestinal	$887.8K	19	3.9%	5
24	Clarithromycin	Antibiotics	$850.0K	17	0.9%	8
25	Furosemide	Diuretics	$700.0K	14	1.0%	10
26	Lactulose	Gastrointestinal	$700.0K	14	5.2%	2
27	Ornidazole	Advanced Antibiotics	$700.0K	14	4.0%	1
28	Tetracycline	Antibiotics	$700.0K	14	4.1%	1
29	Acyclovir	Antivirals	$600.0K	12	0.5%	6
30	Bromhexine	Respiratory & OTC	$600.0K	12	3.7%	6

Lincoln Pharmaceuticals Limited exports 40 pharmaceutical products across 15 therapeutic categories with a total export value of $78.7M. The company is the #1 Indian exporter in 8 products: Diclofenac, Gentamicin, Azithromycin, Griseofulvin, Captopril and 3 more. The top category is Antimalarial & Antiparasitic (20.5% of portfolio), followed by Antibiotics (16.2%), reflecting a diversified portfolio where the top 5 products account for only 45.3% of total value.

Showing top 30 of 40 products. Contact us for complete data.

Lincoln Pharmaceuticals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Lincoln Pharmaceuticals operates two state-of-the-art manufacturing facilities in Gujarat, India. The primary plant is situated in Khatraj, Mehsana district, and is certified by the European Union Good Manufacturing Practice (EU GMP), World Health Organization Good Manufacturing Practice (WHO GMP), and ISO 9001:2015. This facility specializes in producing a wide range of pharmaceutical formulations, including tablets, capsules, injectables, dry syrups, and ointments.

In 2021, Lincoln Pharmaceuticals expanded its production capabilities by acquiring a plant in Mehsana, Gujarat, to manufacture cephalosporin products. This facility is designed to meet the standards of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) and the European Union, and it has received WHO GMP certification. The Mehsana plant focuses on the production of tablets, capsules, dry syrups, and dry powder injections.

3Key Leadership

The leadership team at Lincoln Pharmaceuticals is headed by Managing Director Mahendra G. Patel, who has been instrumental in the company's growth and global expansion. Other key executives include Munjal M. Patel, Ashish R. Patel, Anand A. Patel, and Hasmukhbai I. Patel, who play pivotal roles in the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Lincoln Pharmaceuticals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Lincoln Pharmaceuticals has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility in Khatraj, Gujarat, has been certified by the European Union Good Manufacturing Practice (EU GMP) and the Therapeutic Goods Administration (TGA) of Australia, indicating compliance with stringent international quality standards.

In May 2020, the Khatraj facility received EU GMP certification from EudraGMP, and in October 2021, it obtained approval from Australia's TGA. These certifications enhance Lincoln Pharmaceuticals' ability to export its products to these regulated markets. The company has also been focusing on expanding its presence in the U.S. and U.K. markets, aiming to strengthen its global footprint.

2Emerging Markets

Lincoln Pharmaceuticals has been actively expanding its reach into emerging markets, including Africa, Latin America, and Southeast Asia. The company's manufacturing facilities are approved by over 60 countries' drug authorities, facilitating its entry into these regions. In 2016, Lincoln Pharmaceuticals entered regulated African and Latin American countries, marking a significant milestone in its global expansion strategy.

3Geographic Strategy

Lincoln Pharmaceuticals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of March 2026, Lincoln Pharmaceuticals has not publicly disclosed specific details regarding its FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. The company's focus on obtaining certifications from other regulatory bodies, such as the EU GMP and TGA, suggests a strategic emphasis on markets where these approvals are critical. However, the absence of FDA-specific information may indicate limited direct engagement with the U.S. market or a strategic decision to prioritize other regions.

2WHO & EU GMP

Lincoln Pharmaceuticals' manufacturing facility in Khatraj, Gujarat, has been certified by the World Health Organization Good Manufacturing Practice (WHO GMP) and the European Union Good Manufacturing Practice (EU GMP). These certifications demonstrate the company's commitment to maintaining high-quality manufacturing standards and facilitate its ability to export products to various international markets.

3CDSCO & Indian Regulatory

Lincoln Pharmaceuticals Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Lincoln Pharmaceuticals operates in a competitive landscape with several key players in the Indian pharmaceutical industry. Major competitors include Sun Pharmaceutical Industries, Torrent Pharmaceuticals, and Abbott India. While Lincoln Pharmaceuticals has a diverse product portfolio and a strong presence in various therapeutic areas, it faces competition from these larger entities, which may have more extensive resources and market reach. The company's focus on emerging markets and adherence to international quality standards provide avenues to differentiate itself and capture market share.

2Key Differentiators

Lincoln Pharmaceuticals' key differentiators include its diverse product portfolio across 15 therapeutic categories, adherence to international quality standards with certifications from EU GMP and TGA, and a strategic focus on expanding into emerging markets. The company's manufacturing facilities in Gujarat, India, are designed to meet international standards, enhancing its competitiveness in the global market.

3Strategic Position

Lincoln Pharmaceuticals is strategically positioned as a manufacturer and trader of pharmaceutical products, with a focus on both domestic and international markets. The company's expansion into emerging markets and adherence to international quality standards indicate a strategic direction aimed at global growth. Future outlooks suggest continued emphasis on research and development, regulatory compliance, and market diversification to strengthen its position in the global pharmaceutical industry.

Buyer Due Diligence Brief — Evaluating Lincoln Pharmaceuticals Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Lincoln Pharmaceuticals has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products, with a total export value of $78.7 million USD and 1,763 shipments across 40 products in 15 therapeutic categories. The company's adherence to international quality standards, as evidenced by certifications from EU GMP and TGA, indicates reliability and commitment to product quality. The strategic focus on emerging markets and compliance with regulatory requirements further underscores Lincoln Pharmaceuticals' reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Lincoln Pharmaceuticals as a supplier:

EU GMP Certification: Confirms compliance with European Union Good Manufacturing Practice standards. Verification can be done through the European Medicines Agency (EMA) or the company's official website.

TGA Approval: Indicates compliance with Australia's Therapeutic Goods Administration standards. Verification can be done through the TGA's official website or the company's official website.

Frequently Asked Questions — Lincoln Pharmaceuticals Limited

How many pharmaceutical products does Lincoln Pharmaceuticals Limited export from India?

Lincoln Pharmaceuticals Limited exports 40 pharmaceutical products across 15 therapeutic categories. The top exports are Artesunate ($9.0M), Diclofenac ($8.9M), Metronidazole ($7.0M), Gentamicin ($5.8M), Azithromycin ($4.8M). Total export value is $78.7M.

What is Lincoln Pharmaceuticals Limited's total pharmaceutical export value?

Lincoln Pharmaceuticals Limited's total pharmaceutical export value is $78.7M, based on 1,763 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Lincoln Pharmaceuticals Limited the #1 Indian exporter?

Lincoln Pharmaceuticals Limited is the #1 Indian exporter in 8 products: Diclofenac (2.5% market share), Gentamicin (11.4% market share), Azithromycin (2.6% market share), Griseofulvin (3.5% market share), Captopril (8.1% market share), Aminophylline (16.2% market share), Ornidazole (4.0% market share), Tetracycline (4.1% market share).

What therapeutic categories does Lincoln Pharmaceuticals Limited cover?

Lincoln Pharmaceuticals Limited exports across 15 therapeutic categories. The largest are Antimalarial & Antiparasitic (20.5%, 4 products), Antibiotics (16.2%, 5 products), Advanced Antibiotics (15.9%, 7 products).

Get Full Lincoln Pharmaceuticals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.